



Naomi Pearce

Pearce IP

LEXOLOGY INDEX
HIGHLY RECOMMENDED

- About
- Rankings
- Legal Influencers
- Publications
- Skills & Languages

Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 25 years' experience, and a background in molecular biology/biochemistry.

Amongst other awards, Naomi is ranked in IAM Patent 1000, IAM Strategy 300, is a MIP "Patent Star", WIPR Leader, and a 2022 WIPR "Diversity Champion in IP". She is the 2022 Women in Business Law Asia Pacific "Patent Lawyer of the Year", 2022 Australasian Lawyer "Most Influential Lawyer" in the category of "changemaker", and the 2021 Lawyers Weekly Women In Law SME "Partner of the Year". Naomi is the founder of Pearce IP, which commenced in 2017 and won 2021 "IP Team of the Year" at the Australian Law Awards.

Underpinning Naomi's legal work is a deep understanding of life sciences industries, resulting from first-hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.

Naomi builds elegant market entry strategies which align with clients' commercial objectives, and are anchored with legal and technical excellence. Naomi manages AU patent litigations in the Australian Courts and excels in multi-jurisdictional litigations.

Naom's industry focus is life sciences, with a particular focus on health, pharmaceuticals/ biopharmaceuticals, medical devices, biotechnology, agri/food tech, medical technology, gene editing technologies (including CRISPR), gene therapy, cell therapy, and animal and veterinary healthcare.

Naomi is a biosimilars trailblazer, and has been working on biosimilars since 2003 (before the industry formed).

[Read less](#)

FEEDBACK FROM OUR RESEARCH

"Naomi is a highly strategic thinker and practitioner who thinks not only of local ramifications, but also global ones" "She brings a deep level of commercial insight to her stellar legal advice" "She is hugely knowledgeable on IP issues surrounding commercial aspects of preparing product launch and assessing risks involved"

Contact me by email

Visit firm website

+61 (0) 2 9023 9988

Follow



Lexology Legal Influencer
Q3 | 2025

Rankings in Lexology Index

Client Choice Category: Client Choice - IP - Patents Index Ranking: Highly Recommended	+ READ MORE
Australia & New Zealand Category: Australia & New Zealand - IP - Patents Index Ranking: Recommended	
Australia & New Zealand Category: Australia & New Zealand - Life Sciences Index Ranking: Recommended	
Healthcare & Life Sciences Category: Healthcare & Life Sciences - Patent Litigation Index Ranking: Recommended	
IP Category: IP - Patents Index Ranking: Recommended	

Legal Influencers

Q3 2025 in Dispute resolution - Australasia
Q1 2025 in Dispute resolution - Australasia
Q3 2024 in Healthcare and life sciences - Cross-border
Q2 2024 in Healthcare and life sciences - Australasia
Q2 2024 in Healthcare and life sciences - Cross-border
Q1 2024 in Healthcare and life sciences - Asia-Pacific
Q1 2024 in Healthcare and life sciences - Australasia
Q1 2024 in Healthcare and life sciences - Cross-border
Q4 2023 in Healthcare and life sciences - Asia-Pacific
Q4 2023 in Healthcare and life sciences - US
Q4 2023 in Healthcare and life sciences - Canada
Q4 2023 in Healthcare and life sciences - Australasia
Q4 2023 in Healthcare and life sciences - Europe
Q4 2023 in Healthcare and life sciences - Cross-border
Q3 2023 in Healthcare and life sciences - US
Q3 2023 in Healthcare and life sciences - Cross-border
Q3 2023 in Healthcare and life sciences - Asia-Pacific
Q3 2023 in Healthcare and life sciences - Australasia
Q2 2023 in Healthcare and life sciences - Canada
Q2 2023 in Healthcare and life sciences - US
Q2 2023 in Healthcare and life sciences - Australasia
Q2 2023 in Healthcare and life sciences - Cross-border
Q1 2023 in Healthcare and life sciences - Cross-border
Q4 2022 in Healthcare and life sciences - Cross-border
Q3 2022 in Healthcare and life sciences - Australasia
Q2 2022 in Healthcare and life sciences - Australasia
Q3 2021 in Healthcare and life sciences - Cross-border
Q1 2021 in Healthcare and life sciences - Australasia
Q4 2020 in Healthcare and life sciences - Australasia
Q3 2020 in Healthcare and life sciences - Australasia

[Show less](#)

Publications

Articles
24 Aug 2026 The Domino Effect... AU Federal Court Confirms Compulsory PBS Price Drop Knocks Price of Related Drugs In March this year, Justice Downes of the Federal Court of Australia delivered her decision in Gilead Sciences' (Gilead) case against the Minister...
18 Aug 2026 Pearce IP BioBlast® for the week ending 14 August 2026 Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending...
11 Aug 2026 Pearce IP BioBlast® for the week ending 7 August 2026 Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending...
04 Aug 2026 Pearce IP BioBlast® for the week ending 31 July 2026 Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending...
28 Jul 2026 Pearce IP BioBlast® for the week ending 24 July 2026 On 24 July 2026, Outlook Therapeutics announced that the FDA has approved ONS-5010/Lyteneva™ (bevacizumab-vikg) for the treatment of neovascular...
View more

Skills

Biopharmaceutical	Biosimilar	Gene therapy	Generic drug	Litigation	Patent infringement
Patent term extension	Patents	Pharmaceuticals	Trademarks	Healthcare & Life Sciences	Intellectual Property
Litigation	Patents	Trademarks			

Contact Naomi Pearce

Info@pearceiplaw

+61 (0) 2 9023 9988

Pearce IP

Level 3, 32 Martin Place

2000

Sydney, Australia

LEXOLOGY INDEX

Find out more about Lexology index's research methodology and how you can get involved.

Resources

Daily newsfeed
Panoramic
Research hubs
Learn
In-depth
Lexy Find
Scanner
Contracts & clauses

Lexology Index

Find an expert
Reports
Research methodology
Submissions
FAQ
Instruct Counsel
Client Choice 2025

More

Lexy AI
About us
Legal Influencers
Firms
Blog
Events
Popular
Lexology Academic
Lexology Talent Management

Legal

Terms of use
Cookies
Disclaimer
Privacy policy

Contact

Help centre
Contact
RSS feeds
Submissions

Search Lexology

Follow on X

Follow on LinkedIn